Introduction
============

Maintaining a stable genome is critical for the development and well-being of all organisms. Failure to maintain genome stability is associated with a large variety of diseases, including not only sporadic and inherited cancers but also several neurological, neurodegenerative, neuromuscular, and aging disorders ([@bib21]; [@bib23]; [@bib59]). Although genomic instability is well known to be associated with different diseases, our knowledge about the pathways that protect the organism against genomic instability remains incomplete. However, studies in the model organism *Saccharomyces cerevisiae* have begun to provide a comprehensive description of the pathways and mechanisms that prevent genome instability (for review see [@bib33]). These include mechanisms that protect against reactive oxygen species ([@bib25]), promote fidelity of DNA replication ([@bib9]), function in the S-phase checkpoint response ([@bib52]; [@bib53]), control telomere formation and maintenance ([@bib60]), and assemble newly replicated DNA into chromatin ([@bib54]). In addition, the activity of Cdk1 is crucial to maintain a stable genome ([@bib32]; [@bib35]; [@bib76]; [@bib31]; [@bib17]).

Cdks govern cell cycle progression in eukaryotes. During each phase of the cell cycle, Cdks form a complex with specific cyclins that activate Cdks and help target them to their substrates ([@bib7]). A single Cdk, Cdc28, is sufficient for cell cycle progression in *S. cerevisiae*. Cdc28 controls a plethora of cell cycle--related processes, including specific transcriptional programs associated with each phase of the cell cycle, budding and cell morphogenesis, DNA replication, spindle pole body duplication, and mitotic spindle assembly ([@bib30]; [@bib7]). Cdc28 is also involved in maintenance of telomeres, ([@bib18]; [@bib16]; [@bib80]), contributing to telomere elongation by directly phosphorylating Cdc13 ([@bib38]).

Cdk activity is tightly regulated; several mechanisms, often referred to as checkpoints ([@bib22]), have evolved that target Cdk activity to control the cell cycle in response to environmental and endogenous stresses that might compromise cell viability. For example, cells arrest the cell cycle in response to DNA damage and replication stress ([@bib58]; [@bib66]). The DNA damage and replication checkpoints are defined as the pathways that promote cell cycle delay or arrest in response to DNA damage or DNA replication stress ([@bib22]). In addition, the DNA damage response also involves processes such as recruitment of DNA repair factors ([@bib41]), stabilization of replication forks ([@bib42]), inhibition of late-firing origins of replication ([@bib66]), and cytoplasmic events, including cell morphogenesis ([@bib15]; [@bib71]) and nuclear positioning ([@bib13]). DNA replication stress and DNA damage induce activation of two phosphoinositide 3 kinase--related kinases, Tel1 and Mec1, which are similar to mammalian ataxia telangiectasia mutated (ATM) and ATM and Rad3 related (ATR). These function in the activation of downstream protein kinases, including Chk1 and Rad53 (*S. cerevisiae* Chk2). In *Schizosaccharomyces pombe* and higher eukaryotes, the DNA damage and DNA replication checkpoints inhibit Cdk activity to block cell cycle progression. In contrast, *S. cerevisiae* cells arrest with high Cdc28 activity upon genotoxic stress, and inhibition of Cdc28 activity is not essential for cell cycle arrest ([@bib72]). Instead, upon DNA damage or replication stress, *S. cerevisiae* cells directly target key processes involved in cell cycle progression, including inhibiting the firing of late replication origins and blocking mitosis by preventing precocious chromosome segregation through inhibition of Cin8 and Stu2 as well as by stabilizing Pds1 ([@bib82],[@bib83]; [@bib10], [@bib11]; [@bib66]; [@bib65]; [@bib34]).

The fact that *S. cerevisiae* cells arrest with high Cdc28 activity allows for a function of Cdc28 in the DNA damage response. Indeed, several studies found that Cdc28 has functions in the DNA damage checkpoint activation and response, which may involve direct phosphorylation of Rad9 and Srs2 ([@bib39]; [@bib40]; [@bib29]; [@bib4]; [@bib8]). Furthermore, Cdc28 is important for homologous recombination (HR) during mitosis as well as meiosis ([@bib2]; [@bib29]; [@bib24]). DNA double-strand breaks (DSBs) can be repaired through HR or through nonhomologous end joining (NHEJ), and the choice of either of these pathways depends on the cell cycle: during G1 phase, haploid yeast cells repair DSBs through NHEJ because of the absence of a template for HR, whereas in S and G2/M phases, they preferentially make use of HR ([@bib29]), using the sister chromatid as a template. Furthermore, although Cdc28 is active during the S and G2/M phases of the cell cycle, it is inactive during G1 phase because of low cyclin concentrations and a high abundance of the Cdk inhibitor (CKI) Sic1, and Cdc28 activity determines the mode of DSB repair because its activity is required for resection of the DSB ([@bib29]), which is the first step in HR. The molecular target of Cdc28 in this process was recently identified as the nuclease Sae2, which is directly phosphorylated and activated by Cdc28 ([@bib27]). Efficient resection of a DSB may also involve additional factors such as the Mre11--Rad50--Xrs2 complex, the nucleases Dna2 and Exo1, and the helicase Sgs1 ([@bib19]; [@bib48]; [@bib84]). The exposed single-stranded DNA (ssDNA) is subsequently bound by the replication protein A (RPA) complex, which is later replaced by Rad51. Rad52 then stimulates Rad51 to search for homologous sequences and is also involved in annealing the complementary ssDNA strands ([@bib75]).

In this study, we analyzed the function of Cdc28 in the DNA damage response in more detail. We found that Cdc28 supports cell viability under conditions of chronic DNA damage, but it is not required for survival of acute genotoxic stress, and it does not appear to function as a direct regulator of the DNA damage and replication checkpoints. Furthermore, Cdc28 is part of an extensive genetic network of pathways involved in the maintenance of genome stability, and it cooperates with HR to prevent catastrophic mitotic progression after DNA replication arrest. Surprisingly, we found that Cdc28 activity is also required for formation of gross chromosomal rearrangements (GCRs). Therefore, Cdc28 maintains cell viability during DNA damage while contributing to the formation of genome rearrangements.

Results
=======

Cdc28 promotes cell viability during chronic but not acute DNA damage and is not required for checkpoint activation
-------------------------------------------------------------------------------------------------------------------

To test whether Cdc28 has a function in the response to DNA damage, we made use of two *cdc28* mutants, *cdc28-as1* ([@bib6]) and *cdc28-5M* ([@bib39]). The *cdc28-as1* allele encodes a kinase with an enlarged ATP-binding pocket, allowing it to bind the nonhydrolyzable ATP analogue 1-NM-PP1, and treatment of cells with 1-NM-PP1 results in rapid and highly specific down-regulation of Cdc28 kinase activity ([@bib6]). However, it should be noted that *cdc28-as1* is a hypomorphic allele because the kinase activity of this mutant is reduced by ∼20%, even in the absence of 1-NM-PP1 ([@bib6]). *cdc28-5M* encodes a temperature-sensitive form of Cdc28 with reduced kinase activity at the permissive temperature and further reduced kinase activity leading to lethality at elevated temperatures ([@bib39]). We spotted wild-type (WT) cells, *cdc28-as1* mutants, and *cdc28-5M* mutants on yeast extract/peptone/dextrose (YPD) plates containing increasing but sublethal concentrations of 1-NM-PP1 in the absence or presence of various DNA-damaging agents. As expected, WT cells and *cdc28-5M* mutants were not affected by 1-NM-PP1, whereas the growth of *cdc28-as1* mutants was slightly reduced at 60 and 120 nM 1-NM-PP1 ([Fig. 1](#fig1){ref-type="fig"}). However, these sublethal concentrations of 1-NM-PP1 greatly sensitized *cdc28-as1* mutants to DNA-damaging agents like camptothecin (CPT; which inhibits DNA topoisomerase I), methylmethanesulfonate (MMS; an alkylating agent), hydroxyurea (HU; which depletes deoxynucleoside triphosphates, resulting in DNA replication arrest), and UV irradiation ([Fig. 1](#fig1){ref-type="fig"} and [Fig. S1 A](http://www.jcb.org/cgi/content/full/jcb.200811083/DC1)). Furthermore, *cdc28-as1* mutants were extremely sensitive to phleomycin (which induces free radical--mediated DNA damage, leading to single-strand breaks and DSBs \[[@bib70]\]), even in the absence of 1-NM-PP1, which is likely caused by the fact that Cdc28-as1 has 20% lower kinase activity than WT Cdc28 ([@bib6]). *cdc28-5M* mutants were also very sensitive to MMS, HU, CPT, phleomycin, and UV irradiation ([Fig. 1](#fig1){ref-type="fig"} and Fig. S1 A). These results show that Cdc28 activity is important for cell viability upon chronic exposure to various forms of DNA damage.

![**Cdc28 functions in the DNA damage response.** 10-fold dilutions of log-phase cultures were spotted on YPD supplemented with increasing concentrations of 1-NM-PP1 and fixed concentrations of 10 µg/ml CPT, 0.05% MMS, 100 mM HU, and 1 µg/ml phleomycin (Phleo) or irradiated with 100 J/m^2^ UV, as indicated.](JCB_200811083_GS_Fig1){#fig1}

Unlike other eukaryotes, *S. cerevisiae* cells arrest with high levels of Cdc28 activity after treatment with DNA-damaging agents ([@bib1]). Because Cdc28 activity is required for cell survival in the presence of different types of DNA-damaging agents, it is possible that Cdc28 functions as a checkpoint protein, something which has been suggested previously ([@bib39]; [@bib29]; [@bib4]; [@bib8]). Characteristically, checkpoint mutants do not recover from acute exposure to DNA-damaging agents as they fail to arrest the cell cycle and fail to stabilize replication forks ([@bib42]). To test whether Cdc28 has a checkpoint function, we first arrested WT cells and *cdc28-as1* mutants in G1 phase with α factor and released them into YPD for 30 min to allow cells to go past Start (which is Cdc28 dependent) and enter S phase (which was confirmed by FACS analysis; unpublished data). We then added 1-NM-PP1 for 5 min before treating with either HU or MMS for 2 h. *cdc28-as1* mutants were not more sensitive to killing by HU or MMS ([Fig. 2 A](#fig2){ref-type="fig"}) or phleomycin ([Fig. 2 B](#fig2){ref-type="fig"}) than WT cells. Similar results were obtained with *cdc28-5M* mutants (Fig. S1, B and C). In contrast, mutants lacking the checkpoint protein Rad53 did not survive acute treatment with these agents ([Fig. 2 A](#fig2){ref-type="fig"}).

![**Cdc28 does not have a replication checkpoint function.** (A) Cell survival after HU- or MMS-induced DNA damage does not depend on Cdc28 activity. WT cells or *cdc28-as1* or *rad53* mutants were treated with 10 µM 1-NM-PP1, 200 mM HU, or 0.05% MMS for 2 h, washed, and plated on YPD as described in Materials and methods. Cell survival was calculated as a percentage of untreated WT cells. (B) Cell survival after phleomycin (Phleo)-induced DNA damage does not depend on Cdc28 activity. WT cells or *cdc28-as1* mutants were treated as in A with 1-NM-PP1 and increasing concentrations of phleomycin, and the percentage of cell survival was determined. (A and B) Error bars represent standard deviation. CFU, colony-forming unit.](JCB_200811083_GS_Fig2){#fig2}

To more directly determine whether Cdc28 has an effect on checkpoint activation, we studied the formation of Ddc2 foci. Ddc2 functions in the initiation of DNA damage checkpoint activation by mediating the interaction between Mec1 and the proliferating cell nuclear antigen--like Rad17/Ddc1/Mec3 clamp ([@bib43]). Recruitment of Ddc2 to sites of DNA damage can be visualized by fluorescence microscopy, and formation of Ddc2-GFP foci is used as a quantitative measure for checkpoint activation ([@bib41]). We arrested cells in G1 and released them into YPD for 30 min. We then added 1-NM-PP1 for 5 min to inactivate Cdc28-as1 before treating cells with phleomycin, HU, or MMS. As shown in [Fig. 3 A](#fig3){ref-type="fig"}, Cdc28 was not essential for the formation of Ddc2 foci, which is in accordance with previous findings ([@bib4]). However, although the frequency of Ddc2 focus formation was not affected by Cdc28 activity, we did notice that the intensity of Ddc2 foci was lower in 1-NM-PP1--treated *cdc28-as1* mutants (unpublished data). We also studied the effect of Cdc28 on the formation of spontaneous rather than drug-induced Ddc2 foci in an *mre11Δ* mutant, which accumulates spontaneous DNA damage, resulting in high levels of genome rearrangements ([@bib50]). Although ∼10% of WT cells and *cdc28-as1* mutants had at least one Ddc2 focus, nearly 80% of *mre11Δ* single mutants had Ddc2 foci ([Fig. 3 B](#fig3){ref-type="fig"}). *mre11Δ cdc28-as1* double mutants were similar to *mre11Δ* single mutants, and inhibition of Cdc28-as1 activity by 1-NM-PP1 did not change the frequency of focus formation, although a reduction in the intensity of the foci was observed (unpublished data). We also monitored phosphorylation of Rad53 upon treatment with DNA-damaging agents in WT cells and in *cdc28-as1* mutants. MMS-induced Rad53 activation was not inhibited by 1-NM-PP1 ([Fig. 3 C](#fig3){ref-type="fig"}), indicating that Cdc28 is not required for MMS-induced Rad53 activation, which is similar to the previously reported findings that 4-nitroquinoline 1-oxide--induced Rad53 activation is independent of Cdc28 ([@bib29]) and that Cdc28 by itself is not essential for Rad53 activation ([@bib4]). Interestingly, we found that phleomycin-induced Rad53 phosphorylation was partially reduced in 1-NM-PP1--treated *cdc28-as1* mutants, indicating that checkpoint activation by phleomycin-induced DNA damage may be partially dependent on Cdc28 ([Fig. 3 D](#fig3){ref-type="fig"}).

![**Cdc28 has no major role in DNA damage--induced checkpoint activation.** (A) DNA damage--induced formation of Ddc2 foci is independent of Cdc28. Cells were arrested with α factor and released into YPD or YPD containing 10 µM 1-NM-PP1 and the indicated DNA-damaging agents for 2 or 4 h, as indicated (see Materials and methods). Ddc2-GFP foci were visualized using fluorescence microscopy, and the percentage of cells with foci relative to the total cell population of that specific sample was calculated. Phleo, phleomycin. (B) Checkpoint activation upon endogenous DNA damage does not depend on Cdc28 activity. WT cells and *cdc28-as1*, *mre11Δ*, and *cdc28-as1 mre11Δ* mutants were arrested in α factor before being released into YPD supplemented with 10 µM 1-NM-PP1 for 2 h, and the percentage of cells with Ddc2-GFP foci were determined as described in A. Error bars represent standard deviation. (C) MMS-induced phosphorylation of Rad53 is independent of Cdc28. WT cells and *cdc28-as1* mutants were arrested in α factor (α) and released into YPD for 30 min to allow cells to enter S phase. Then, either DMSO or 1-NM-PP1 was added to inactivate Cdc28-as1 (time point 0) followed by treatment with MMS for 30, 60, or 120 min. Cell lysates were analyzed by Western blotting using Flag antibodies to detect Rad53. (D) Phleomycin-induced phosphorylation of Rad53 is partially dependent on Cdc28. WT cells and *cdc28-as1* mutants were arrested in α factor and released into YPD for 30 min to allow cells to enter S phase. Then, either DMSO or 1-NM-PP1 was added to inactivate Cdc28-as1 (time point 0) followed by treatment with phleomycin for 60, 120, or 180 min. Cell lysates were analyzed by Western blotting using Flag antibodies to detect Rad53. (E) Cdc28 is not required for MMS-induced S-phase arrest. WT cells and *cdc28-5M* and *rad53Δ* mutants were grown into log phase (log) or arrested in α factor before being released into YPD supplemented with 0.05% MMS. Samples were taken at the indicated time points and analyzed by FACS. (F) Checkpoint inactivation after replication arrest does not require Cdc28 activity. WT cells and *cdc28-as1* mutants were arrested in HU for 3 h before HU was washed away, and cells were resuspended in YPD supplemented with either DMSO or 10 µM 1-NM-PP1. Samples were taken at the indicated time intervals, and Rad53 phosphorylation was analyzed as in C. P-Rad53, phospho-Rad53.](JCB_200811083_GS_Fig3){#fig3}

We also used FACS to determine whether Cdc28 is involved in the arrest of the cell cycle in response to MMS-induced DNA replication damage. We synchronized WT cells, *rad53Δ* mutants and *cdc28-5M* mutants in G1 and released them in YPD supplemented with 0.05% MMS. As shown in [Fig. 3 E](#fig3){ref-type="fig"}, WT cells arrested the cell cycle in the presence of MMS, whereas *rad53Δ* mutants, which are checkpoint defective, did not show slow progression through the cell cycle. *cdc28-5M* mutants, which are very sensitive to MMS even at the permissive temperature ([Fig. 1](#fig1){ref-type="fig"}), entered S phase somewhat later than WT cells after release from α factor but efficiently arrested the cell cycle, indicating that Cdc28 is not required for activation of the checkpoint.

Another reason why mutants with reduced Cdc28 activity might be sensitive to DNA damage is that they might not recover from checkpoint activation, which is similar to what has been described for mutants lacking the phosphatases Ptc2, Ptc3, and Pph3 that down-regulate the checkpoint by dephosphorylating Rad53 ([@bib36]; [@bib56]). To test whether Cdc28 may have a function in recovery from DNA replication arrest, we arrested WT cells and *cdc28-as1* mutants in S phase for 3 h with HU and released them into either YPD or YPD supplemented with 1-NM-PP1. As shown in [Fig. 3 F](#fig3){ref-type="fig"}, in WT cells, Rad53 was largely dephosphorylated 1 h after release from HU arrest and almost completely dephosphorylated 2 h after release, indicating down-regulation of the checkpoint. The degree of Rad53 dephosphorylation in *cdc28-as1* mutants was identical to that of WT cells and was not impaired by 1-NM-PP1, indicating that Cdc28 is not required for turning off the checkpoint. In addition, FACS analysis showed that both WT cells and *cdc28-as1* mutants had completed DNA replication 1 h after release from HU arrest, and this also was not affected by 1-NM-PP1 (unpublished data). Therefore, although Cdc28 is important for cell viability during chronic exposure to DNA damage, it is not important for cell survival after acute DNA damage, and, by itself, it does not appear to have a major role in either the activation or down-regulation of DNA damage or replication checkpoints.

Cdc28 functions with Mre11 in recovery from DNA replication arrest
------------------------------------------------------------------

Although Cdc28 by itself may not be required to recover from DNA replication arrest, it might cooperate with certain DNA repair pathways for recovery and resumption of the cell cycle. Indeed, we found that *CDC28* genetically interacts with many pathways involved in the maintenance of genome stability, including HR (see next section). To explore the possibility that Cdc28 cooperates with HR in recovery from DNA replication arrest, we made use of FACS analysis to test the ability of WT cells, *cdc28-5M* and *mre11Δ* single mutants, and *cdc28-5M mre11Δ* double mutants to recover from S-phase arrest and to go through M phase by treating them with HU and releasing them into medium containing α factor. Mutants that do not recover from replication arrest should be unable to complete M phase or to exit from M phase. We made use of the *cdc28-5M* allele because Cdc28-5M has strongly reduced kinase activity even at permissive temperatures ([@bib39]) while retaining sufficient kinase activity to allow cells to go through M phase (inhibition of Cdc28 activity using 1-NM-PP1 treatment of *cdc28-as1* mutants results in complete M-phase arrest \[[@bib6]\] and, therefore, is not suitable for studying exit from M phase). As shown in [Fig. 4 A](#fig4){ref-type="fig"}, after 40 min, WT cells had recovered from HU arrest and completed bulk DNA synthesis. All cells had exited from M phase and accumulated in G1 phase after 180 min. The *cdc28-5M* single mutant also completed DNA synthesis after 40 min but exited from M phase slower than WT, accumulating in G1 phase after 180 min ([Fig. 4 B](#fig4){ref-type="fig"}). Interestingly, a portion of *cdc28-5M* mutants accumulated with sub-G1 DNA content, indicating a certain degree of mitotic catastrophe, which is consistent with a previous study implicating Cdc28 in prevention of mitotic catastrophe ([@bib32]). *mre11Δ* mutants were delayed in passing through M phase ([Fig. 4 C](#fig4){ref-type="fig"}), although a relatively large number of cells ultimately accumulated in G1 phase. However, the *mre11Δ cdc28-5M* double mutant had a strong defect in recovering from DNA replication arrest, as the majority of cells were unable to progress through M phase ([Fig. 4 D](#fig4){ref-type="fig"}). In addition, those cells that did manage to exit from M phase appeared to have \<1 N DNA content, as indicated by the absence of a distinct G1-phase peak and the presence of a large sub--G1 phase population instead. We also made use of pulsed-field gel electrophoresis (PFGE) to monitor chromosomal integrity. We found that log-phase WT cells had very low levels of chromosome fragmentation, which increased after treatment with HU ([Fig. 4 E](#fig4){ref-type="fig"} and [Fig. S2](http://www.jcb.org/cgi/content/full/jcb.200811083/DC1)). *mre11Δ* mutants had levels of chromosome fragmentation that were comparable with that of WT cells. Interestingly, log-phase *cdc28-5M* mutants showed increased chromosome fragmentation ([Fig. 4 E](#fig4){ref-type="fig"}), although this was not further increased by HU treatment. Furthermore, *mre11Δ cdc28-5M* double mutants did not have higher levels of chromosome fragmentation than *cdc28-5M* single mutants. Collectively, these results indicate that Cdc28 cooperates with Mre11 to prevent catastrophic M-phase progression after DNA replication stress.

![**Cdc28 cooperates with Mre11 to maintain genome stability.** Cdc28 cooperates with Mre11 to prevent mitotic catastrophe after DNA replication arrest. (A--D) WT cells (A), *cdc28-5M* mutants (B), *mre11Δ* mutants (C), and *mre11Δ cdc28-5M* double mutants (D) were arrested in HU for 3 h before being released into YPD supplemented with α factor at 30°C. Samples were taken at the indicated time intervals and analyzed using FACS analysis. (E) Cdc28 prevents chromosome fragmentation. WT cells and *mre11Δ*, *cdc28-5M*, and *mre11Δ cdc28-5M* mutants were treated as indicated, and whole chromosomes were analyzed by PFGE. The relative amount of chromosome fragmentation (at 30°C because incubation at 37°C did not further increase fragmentation) was calculated as described in Materials and methods. Error bars represent the standard error of the mean.](JCB_200811083_GS_Fig4){#fig4}

Cdc28 is required for the formation of GCRs
-------------------------------------------

To further characterize the effect of Cdc28 on the maintenance of genome stability, we analyzed its effect on GCR formation. First, we measured GCR rates in strains with increased Cdc28 activity generated by deleting genes encoding endogenous inhibitors of Cdc28. Mutants lacking the CKI Sic1 (the functional homologue of mammalian p27^KIP1^ \[[@bib3]\]), which prevents precocious entry into S phase by inhibiting cyclin B--Cdc28 complexes ([@bib68]), had a 17-fold increase in GCR rate ([Table I](#tbl1){ref-type="table"}). This is significantly lower than the ∼600--fold increase that has been published previously ([@bib35]) but consistent with the 19-fold increase in GCR rates obtained with overexpression of *CLN2-1*, which encodes a stabilized form of Cln2 that also induces precocious entry into S phase by elevating the activity of Cdc28 ([@bib76]). In addition, deletion of *FAR1*, a CKI that directly inhibits cyclin--Cdc28 complexes to prevent entry into S phase ([@bib62]), resulted in a similar increase in GCR rates ([Table I](#tbl1){ref-type="table"}), whereas simultaneous deletion of *SIC1* and *FAR1* appeared to result in an additive effect, leading to a 33-fold increase in GCR rates ([Table I](#tbl1){ref-type="table"}). Mutants lacking Swe1, the budding yeast homologue of mammalian Wee1 that directly phosphorylates and inhibits Cdc28 to inhibit entry into M phase when certain aspects of cytoskeletal function or bud formation are impaired ([@bib37]), did not have increased GCR rates ([Table I](#tbl1){ref-type="table"}). Therefore, consistent with previous findings ([@bib35]; [@bib76]), unscheduled activation of Cdc28 during G1--S phase resulted in increased GCR rates, reiterating the belief that most GCRs stem from processes related to DNA replication (for review see [@bib33]).

###### 

Mutations in *CDC28* suppress GCR rates

  Relevant genotype                                         Mutation rate (Can^r^ − 5FOA^r^) (×10^−10^)                                                          
  --------------------------------------------------------- -------------------------------------------------- ------------------------------------------------- -----------------------------------------------
                                                            *CDC28*                                            *cdc28-as1*                                       *cdc28-5M*
  WT                                                        3.50 (1)[a](#tblfn1){ref-type="table-fn"}          \<12.5 (\<3.6)[b](#tblfn2){ref-type="table-fn"}   \<128 (\<37)[b](#tblfn2){ref-type="table-fn"}
  **CKIs**                                                                                                                                                       
  *sic1Δ*                                                   59.5 (17)                                          NT                                                NT
  *far1Δ*                                                   71.1 (20)                                          NT                                                NT
  *sic1Δ far1Δ*                                             115.9 (33)                                         NT                                                NT
  *swe1Δ*                                                   \<5.69 (\<1.6)[b](#tblfn2){ref-type="table-fn"}    NT                                                NT
  **HR**                                                                                                                                                         
  *rad50Δ*                                                  2,300 (657)[a](#tblfn1){ref-type="table-fn"}       148 (42)                                          NT
  *mre11Δ*                                                  2,490 (711)                                        128 (37)                                          \<327 (93)[b](#tblfn2){ref-type="table-fn"}
  *mre11Δ* in nocodazole[g](#tblfn7){ref-type="table-fn"}   5,700 (1,622)                                      NT                                                NT
  *mre11Δ* in SC, RT[h](#tblfn8){ref-type="table-fn"}       1,890 (543)                                        NT                                                NT
  *mre11Δ yku80Δ*                                           6,156 (1,759)                                      542 (155)                                         NT
  *rad52Δ*                                                  350 (100)[c](#tblfn3){ref-type="table-fn"}         290 (83)                                          \<446 (127)[b](#tblfn2){ref-type="table-fn"}
  *sae2Δ*                                                   177 (51)                                           \<67 (\<19)[b](#tblfn2){ref-type="table-fn"}      NT
  *sae2Δ mre11Δ*                                            2,798 (797)                                        NT                                                NT
  **DNA damage and replication checkpoint**                                                                                                                      
  *mec1Δ*                                                   680 (194)[d](#tblfn4){ref-type="table-fn"}         NT                                                \<33 (\<9)[b](#tblfn2){ref-type="table-fn"}
  *mec1Δ tel1Δ*                                             45,000 (12,857)[d](#tblfn4){ref-type="table-fn"}   NT                                                2,390 (683)
  *rad53Δ*                                                  95 (27)[d](#tblfn4){ref-type="table-fn"}           \<9.6 (\<2.7)[b](#tblfn2){ref-type="table-fn"}    NT
  *pds1Δ*                                                   670 (190)[d](#tblfn4){ref-type="table-fn"}         \<64 (\<18)[b](#tblfn2){ref-type="table-fn"}      NT
  *rfc5-1Δ*                                                 660 (189)[d](#tblfn4){ref-type="table-fn"}         \<5.1 (\<1.5)[b](#tblfn2){ref-type="table-fn"}    NT
  *rad17Δ*                                                  30 (9)[d](#tblfn4){ref-type="table-fn"}            \<14 (\<4)[b](#tblfn2){ref-type="table-fn"}       NT
  *rad24Δ*                                                  40 (11)[d](#tblfn4){ref-type="table-fn"}           \<26 (\<7.4)[b](#tblfn2){ref-type="table-fn"}     NT
  **Others**                                                                                                                                                     
  *sgs1Δ*                                                   77 (22)[e](#tblfn5){ref-type="table-fn"}           60 (17)                                           \<74 (\<21)[b](#tblfn2){ref-type="table-fn"}
  *rfa1-t11 (CEN)*                                          420 (120)[a](#tblfn1){ref-type="table-fn"}         \<69 (\<20)[b](#tblfn2){ref-type="table-fn"}      NT
  *rad27Δ*                                                  4,400 (1,257)[e](#tblfn5){ref-type="table-fn"}     NT                                                \<277 (\<79)[b](#tblfn2){ref-type="table-fn"}
  *tsa1Δ*                                                   173 (49)[f](#tblfn6){ref-type="table-fn"}          NT                                                \<84 (24)[b](#tblfn2){ref-type="table-fn"}
  *pif1Δ*                                                   3,530 (1,008)[c](#tblfn3){ref-type="table-fn"}     519 (148)                                         200 (57)

NT, not tested. Numbers in parentheses indicate fold increase over WT. The mutation rates are shown as events per generation.

Data from [@bib9].

GCR rates could not be accurately calculated because GCRs were not detected in a large enough proportion of the cultures.

Data from [@bib50].

Data from [@bib52].

Data from [@bib51].

Data from [@bib25].

*mre11Δ* mutants were grown in 10 µM nocodazole until stationary phase to test the effect of delaying the cell cycle on GCR rates.

*mre11Δ* mutants were grown in synthetic complete medium (SC) at RT until stationary phase to test the effect of delaying the cell cycle on GCR rates.

Because increased Cdc28 activity resulted in increased GCR rates, we next asked what the effect would be of reduced Cdc28 activity on GCR rates. Typically, mutations in genes that are involved in the DNA damage response lead to increased GCR rates, presumably because damaged chromosomes are not faithfully repaired (for review see [@bib33]). Therefore, because we found that Cdc28 is involved in the response to DNA damage ([Fig. 1](#fig1){ref-type="fig"} and Fig. S1 A), we expected *cdc28* mutants to have increased GCR rates. However, we did not observe a single GCR event in cultures of either *cdc28-as1* or *cdc28-5M* mutants and, therefore, could only calculate an upper limit for the GCR rate of these strains ([Table I](#tbl1){ref-type="table"}); the actual rate is likely to be lower. We next tested whether *cdc28* mutations can suppress the increased GCR rates caused by well-known mutator mutations such as *mre11Δ* and *rad50Δ* ([@bib50]). As shown in [Table I](#tbl1){ref-type="table"}, *mre11Δ* and *rad50Δ* single mutants have GCR rates that are ∼700-fold higher than WT. However, even in the absence of 1-NM-PP1, *mre11Δ cdc28-as1* and *rad50Δ cdc28-as1* double mutants only had ∼40-fold increased GCR rates. Thus, a modest reduction in Cdc28 activity was sufficient to largely suppress GCR rates of *mre11Δ* and *rad50Δ* mutants. In addition, cultures of *mre11Δ cdc28-5M* double mutants did not form even a single GCR, and, therefore, accurate GCR rates could not be calculated for this strain. The increased GCR rate of mutants lacking Rad52 was also suppressed by *cdc28* mutations ([Table I](#tbl1){ref-type="table"}).

One might argue that the suppressive effect of *cdc28* mutations on GCR rates might be caused by the reduced speed with which the mutants traverse the cell cycle. We tested that possibility by artificially reducing growth rates by culturing *mre11* mutants at RT in synthetic complete media. These conditions substantially reduced growth rates of this mutant (unpublished data) but had basically no effect on the GCR rate, which was 543-fold over WT ([Table I](#tbl1){ref-type="table"}). In addition, we cultured *mre11* mutants in YPD supplemented with a sublethal dose (10 µM) of nocodazole, which strongly reduced the growth rate of this mutant, taking up to 5 d to reach stationary phase (unpublished data). However, this treatment resulted in increased rather than decreased GCR rates of *mre11* mutants (∼1,622-fold over WT; [Table I](#tbl1){ref-type="table"}). Therefore, the suppression of GCR formation by hypomorphic *cdc28* alleles is not a result of the reduced speed with which these mutants pass through the cell cycle. Alternatively, the suppressive effect of *cdc28-as1* and *cdc28-5M* on formation of GCRs in *mre11Δ* mutants could also be a result of the reduced activity of the nuclease Sae2. Cdc28 has recently been shown to phosphorylate and thereby stimulate the activity of Sae2, resulting in the resection of DSBs to expose ssDNA, which is the first step in HR ([@bib27]). One could argue that mutants harboring *cdc28* alleles suppress the GCRs that arise in HR-defective *mre11Δ* mutants because Cdc28 is unable to fully activate Sae2, thereby preventing resection and futile attempts to perform HR that might otherwise lead to GCRs. The DSBs might be channeled into the NHEJ pathway instead, resulting in an apparent reduction in GCR rates. If this model were correct, one would predict that depleting Sae2 would result in suppression of the GCR rates of *mre11Δ* mutants. Conversely, inactivation of the NHEJ pathway by deleting *YKU80* in an *mre11Δ cdc28-as1* background should then restore GCR rates. However, we found that a *sae2Δ* single mutant had a GCR rate of ∼50-fold over WT, and a *sae2Δ mre11Δ* double mutant had a GCR rate of ∼797-fold over WT, which is identical to that of *mre11Δ* single mutants ([Table I](#tbl1){ref-type="table"}). Furthermore, the GCR rate of *sae2Δ* mutants was suppressed by the *cdc28-as1* allele. Finally, *yku80Δ mre11Δ cdc28-as1* triple mutants had a GCR rate of 155-fold over WT, compared with 1,759-fold for *yku80Δ mre11Δ* double mutants ([Table I](#tbl1){ref-type="table"}). We conclude that channeling of DSBs into the NHEJ pathway is not involved in *cdc28*-mediated suppression of GCRs because (a) deletion of *SAE2* does not result in suppression of GCRs and therefore failure to fully activate Sae2 cannot explain the suppressive effect of *cdc28* mutations on formation of GCRs, and (b) deletion of *YKU80* does not restore the suppressed GCR rates of *mre11Δ cdc28-as1* mutants.

We also determined the effect of *cdc28-as1* and *cdc28-5M* mutations on the GCR rates of cells with deletions in various DNA damage and replication checkpoint genes, including *RAD17*, *RAD24*, *RAD53*, *MEC1*, and a combination of *MEC1* and *TEL1*. In all cases, mutations in *CDC28* suppressed the increased GCR rates ([Table I](#tbl1){ref-type="table"}), and in most cases, no GCR events could be detected in mutants in the *cdc28-5M* background. The one exception was the *mec1Δ tel1Δ cdc28-5M* triple mutant, which had a GCR rate that was increased ∼700-fold over the WT rate; however, because *mec1Δ tel1Δ* double mutants have a GCR rate that is increased 12,000-fold over the WT rate, the *cdc28-5M* mutation was still a potent suppressor of GCRs. The *cdc28-as1* and *cdc28-5M* mutations also suppressed GCR rates of *rfa1-t11*, *rfc5-1*, *tsa1Δ*, *pds1Δ*, *asf1Δ*, *sgs1Δ*, *rad27Δ*, and *tsa1Δ* mutants and at least partially suppressed the increased GCR rate of a *pif1Δ* mutant, which acquires GCRs that are exclusively de novo telomere additions. In conclusion, these data show that mutations in *CDC28* have a broad suppressive effect on the increased accumulation of GCRs in many mutant backgrounds, indicating a general requirement for Cdc28 activity in formation of GCRs.

Cdc28 activity does not suppress the increased mutation rate caused by an *msh2* mutation
-----------------------------------------------------------------------------------------

To determine whether Cdc28 also affects the accumulation of mutations like base substitutions and frameshifts, we made use of three mutator assays: the *CAN1* forward mutation assay, which scores for mutations that inactivate the *CAN1* gene, the *lys2-Bgl* reversion assay, which detects reversion of a +4 insertion in the *LYS2* gene, and the *hom3-10* reversion assay, which detects reversion of a +1 insertion in the *HOM3* gene. The *lys2-Bgl* and the *hom3-10* assays are particularly sensitive for detecting defects in mismatch repair, whereas the *CAN1* assay detects a broad range of mutator phenotypes ([@bib47]; [@bib20]; [@bib77]; [@bib78]; [@bib79]). As shown in [Table II](#tbl2){ref-type="table"}, the *cdc28-5M* mutation did not affect mutation rates in any of these assays. Furthermore, the *cdc28-5M* mutation did not suppress the high mutation rates of mutants lacking the Msh2 mismatch repair protein. Therefore, it seems likely that Cdc28 might specifically affect the processing or the stability of broken chromosomes that underlie the formation of GCRs.

###### 

Reduced Cdc28 activity does not affect non-GCR mutation rates

  Relevant genotype   Hom^+^ rate (×10^−8^)    Lys^+^ rate (×10^−8^)   Can^r^ rate (×10^−7^)
  ------------------- ------------------------ ----------------------- -----------------------
  WT                  1.4 (1.2--1.5)           1.9 (1.4--2.7)          3.6 (3.1--5.2)
  *cdc28-5M*          1.2 (0.8--1.6)           1.8 (1.6--2.5)          2.3 (1.9--5.8)
  *msh2Δ*             670.2 (405.9--832.8)     62.1 (50.8--99.0)       34.6 (16.6--48.8)
  *msh2Δ cdc28-5M*    967.7 (505.4--1,730.9)   55.3 (45.1--73.6)       39.3 (31.4--67.6)

Numbers in parentheses indicate confidence intervals. The mutation rates are shown as events per generation.

*CDC28* is part of a genetic network that preserves chromosomal stability
-------------------------------------------------------------------------

We next wanted to gain insight into the genetic network that involves *CDC28* and that promotes cell survival. We made use of a directed chemical--genetics approach to test for genetic interactions between *cdc28-as1* and defects in the major pathways involved in maintenance of genome stability. We spotted double mutants on either YPD plates supplemented with DMSO or YPD plates containing 200 nM 1-NM-PP1, which is a sublethal concentration that still permits growth of *cdc28-as1* single mutants. We found that a variety of genetic pathways function with *CDC28* to maintain cell viability ([Table III](#tbl3){ref-type="table"} and [Fig. S3 A](http://www.jcb.org/cgi/content/full/jcb.200811083/DC1)). For instance, *CDC28* genetically interacted with genes involved in HR (*MRE11*, *RAD50*, *RAD52*, and *POL32*), sister chromatid cohesion (*CTF4* and *CTF18*), the DNA replication and DNA damage checkpoints (*RAD53* and a combination of *MEC1* and *TEL1*), the spindle checkpoint and mitotic exit network (*BUB3*, *MAD2*, and *BUB2*), the RNA component of telomerase (*TLC1*), DNA replication (*RFA1*), flap endonuclease (*RAD27*), and chromatin remodeling (*ASF1*). *CDC28* also showed strong genetic interactions with components of the postreplication repair pathway, particularly *RAD6*, and also with *RAD18* and *RAD5*. Deletion of *RAD6* resulted in synthetic lethality in a *cdc28-5M* background ([Fig. 5 A](#fig5){ref-type="fig"}), which was rescued by a plasmid harboring WT *RAD6* ([Fig. 5 B](#fig5){ref-type="fig"}) but not by a plasmid encoding the catalytically inactive Rad6-C88A mutant (not depicted) and was partially rescued by a plasmid harboring *rad6-149*, which encodes a mutant of Rad6 that lacks the acidic C terminus and which is particularly deficient in ubiquitination of histones ([@bib74]; [@bib64]). We also found genetic interactions between *CDC28* and *BRE1* and *LGE1*, whose gene products function in complex with Rad6 in H2B ubiquitination ([@bib28]; [@bib81]). All of the genetic interactions with *CDC28* that we observed in this study were seen under conditions of chronic but not acute inhibition of Cdc28; a brief treatment of each of the double mutants with 1-NM-PP1 resulted in little or no loss of cell viability (Fig. S3 B). The fact that a brief inhibition of Cdc28 in these mutants is reversible indicates that these double mutants may have to go through several rounds of the cell cycle under conditions of reduced Cdc28 activity before losing cell viability, which could potentially be the result of chromosome loss events. Finally, using a bioinformatics approach (see Materials and methods), we identified additional genetic interactions between *CDC28* and genes previously implicated in the maintenance of genome stability ([Table S1](http://www.jcb.org/cgi/content/full/jcb.200811083/DC1); [@bib57]). Although we did not confirm every predicted genetic interaction, we found that 14 out of 18 (78%) genes tested genetically interacted with *CDC28*. Therefore, our methodology for prediction of genetic interactions should be widely applicable. An overview of the *CDC28* genetic network involved in maintenance of genome stability is shown in [Fig. 5 C](#fig5){ref-type="fig"}; *CDC28* genetically interacts with a wide range of pathways involved in genome stability, thus underscoring the importance of Cdc28 in this process.

###### 

Genetic interactions with *CDC28*

  Relevant genotype                            Sensitivity to 200 nM 1-NM-PP1   
  -------------------------------------------- -------------------------------- ------
  WT                                           −                                −
  **Recombination**                                                             
  *mre11Δ*                                     −                                ++++
  *rad50Δ*                                     −                                ++++
  *rad51Δ*                                     −                                \+
  *rad52Δ*                                     −                                +++
  *rad54Δ*                                     −                                −
  *pol32Δ*                                     −                                ++++
  *sae2Δ*                                      −                                \+
  **RPA complex**                                                               
  *rfa1-t6*                                    −                                ++++
  *rfa1-t11*                                   −                                ++++
  *rfa1-t19*                                   −                                ++++
  *rfa1-t48*                                   −                                ++++
  **NHEJ**                                                                      
  *yku80Δ*                                     −                                \+
  *lig4Δ*                                      −                                −
  **Replication fork progression**                                              
  *top3Δ*                                      −                                \+
  *sgs1Δ*                                      −                                \+
  *rrm3Δ*                                      −                                −
  *srs2Δ*                                      −                                −
  *mus81Δ*                                     −                                −
  *mus81Δ mms4Δ*                               −                                −
  *slx1Δ*                                      −                                +++
  **Nucleotide excision repair**                                                
  *rad10Δ*                                     −                                −
  **Okazaki fragments**                                                         
  *rnh201Δ rnh203Δ*                            −                                −
  *rad27Δ*                                     −                                ++++
  **Postreplication repair**                                                    
  *rad5Δ*                                      −                                ++
  *rad6Δ*                                      −                                ++++
  *rad18Δ*                                     −                                ++
  *pol30-119*                                  −                                \+
  **DNA damage and replication checkpoints**                                    
  *rad17Δ*                                     −                                −
  *rad24Δ*                                     −                                −
  *rfc5-1*                                     −                                \+
  *elg1Δ*                                      −                                \+
  *tof1Δ*                                      −                                \+
  *csm3Δ*                                      −                                ++
  *mec1Δ*                                      −                                −
  *tel1Δ*                                      −                                −
  *mec1Δ tel1Δ*                                −                                ++
  *rad53Δ*                                     −                                ++
  *chk1Δ*                                      −                                −
  **Spindle checkpoint/ mitotic exit**                                          
  *bub3Δ*                                      −                                ++++
  *mad2Δ*                                      −                                +++
  *bub2Δ*                                      −                                +++
  **Sister chromatid cohesion**                                                 
  *ctf4Δ*                                      −                                ++++
  *ctf18Δ*                                     −                                ++++
  **Chromatin organization**                                                    
  *asf1Δ*                                      −                                +++
  *cac1Δ*                                      −                                −
  **Telomeres**                                                                 
  *pif1Δ*                                      −                                −
  *tlc1Δ*                                      −                                ++++
  **Oxidative stress response**                                                 
  *tsa1Δ*                                      −                                −
  **Cdc28 regulation**                                                          
  *sic1Δ*                                      −                                −

−, not more sensitive/equally sensitive to *cdc28-as1*; +, slightly slower growth compared with *cdc28-as1* single mutant; ++, slow growth compared with *cdc28-as1* single mutant; +++, severely reduced growth compared with *cdc28-as1* single mutant; ++++, near death or dead compared with *cdc28-as1* single mutant.

![***CDC28* genetically interacts with pathways involved in maintenance of genome stability.** (A) Synthetic lethal interaction between *cdc28-5M* and *rad6Δ*. *CDC28/cdc25-5M RAD6/rad6Δ* diploids were sporulated, and tetrads were dissected. All combinations except the *rad6 cdc28-5M* double mutant were observed. (B) Expression of *rad6-149* partially rescues the synthetic lethality of the *cdc28-5M rad6Δ* mutant. 10-fold dilutions of log-phase cell cultures were spotted on YPD plates and incubated until colonies were visible. (C) *CDC28* genetic interaction map.](JCB_200811083_RGB_Fig5){#fig5}

Discussion
==========

*CDC28* is required for survival of chronic but not acute DNA damage
--------------------------------------------------------------------

The role of Cdc28 in DNA damage--induced checkpoint activation is currently unclear. It has been shown that Cdc28 is required for checkpoint activation after induction of a homothallic switching (HO) endonuclease break during the G2 phase but not the G1 phase of the cell cycle ([@bib29]). Furthermore, artificial recruitment of Ddc1-lacI (which recruits the Ddc1--Mec1 complex) and Ddc2-lacI (which recruits the 9-1-1 complex that consists of Ddc2, Mec3, and Rad17) chimaeras to a chromosomal array of lac operators has been shown to induce Rad53 phosphorylation even in the absence of DNA damage, and this was dependent on Cdc28-mediated phosphorylation of Rad9 ([@bib8]). In another study, it was reported that Cdc28 was important for Ddc2 foci formation but, by itself, is not required for ionizing radiation--induced Rad53 phosphorylation ([@bib4]); rather, Cdc28 had a redundant role with RPA in the activation of Rad53 ([@bib4]). In this study, we have shown that Cdc28 functions in the maintenance of cell viability in the presence of various types of DNA damage, including HU-induced replication fork stalling, alkylation of DNA (MMS), cross-linked nucleotides (UV) and free radical--mediated DNA damage (phleomycin). However, Cdc28 by itself did not seem to have a major effect on either checkpoint activation or cell survival upon acute exposure to most of these types of DNA-damaging agents, indicating that Cdc28 is not a key regulator of checkpoint responses to most types of DNA damage. We only observed a partial effect of Cdc28 on Rad53 phosphorylation after phleomycin treatment, which is thought to induce DSBs ([@bib70]). Because phleomycin-induced formation of Ddc2-GFP foci in *cdc28-as1* mutants was not affected by 1-NM-PP1, Cdc28 appears to have a function downstream of Ddc2 but upstream of Rad53, which is in accordance with a previous study showing that Cdc28 might be important for Rad9 activity ([@bib8]). Apart from this, our finding that Cdc28 by itself was not a major player in checkpoint activation seems at variance with previous studies that implicate Cdc28 in checkpoint activation ([@bib29]; [@bib4]; [@bib8]). One explanation might be that Cdc28 is involved in DNA damage checkpoint activation by DSBs that are induced by HO breaks ([@bib29]), γ irradiation ([@bib4]), and, to a certain extent, by phleomycin (this study), but Cdc28 might not be required for checkpoint activation after DNA-damaging treatments that mainly result in replication fork stalling such as MMS and HU. Furthermore, the effect of Cdc28 on DNA damage checkpoint activation has thus far mainly been studied in cells that were arrested in either G1 phase or in G2/M phase ([@bib39]; [@bib29]; [@bib4]; [@bib8]), whereas we studied the effect of DNA damage in S phase. It was recently shown that DNA damage during S phase results in much more potent checkpoint activation than during either G1 phase or G2/M phase as a result of replication fork stalling ([@bib85]). Because we used the replication fork stalling agents MMS and HU, it is possible that checkpoint activation by stalled replication forks may either not require Cdc28 or it might result in such a strong signal that the requirement for Cdc28 is overridden.

Although Cdc28 activity alone did not appear to be involved in recovery from replication checkpoint arrest, we found that it cooperates with Mre11 to prevent mitotic catastrophe after replication arrest. Cdc28 has previously been shown to be required for the resection step of HR ([@bib2]; [@bib29]; [@bib24]), but our finding that *CDC28* is not epistatic to *MRE11* and *RAD52* ([Tables I](#tbl1){ref-type="table"} and [III](#tbl3){ref-type="table"}) indicates that Cdc28 likely has additional functions as well. We currently do not know the nature of this function, but based on the results of our GCR assays (see next section), we speculate that Cdc28 may somehow help prevent loss of damaged chromosomes, as has been suggested previously ([@bib32]; [@bib31]).

Cdc28 activity is required for formation of GCRs
------------------------------------------------

We evaluated the function of *CDC28* in formation of GCRs and found that Cdc28 activity directly correlated with the rate of GCR formation; augmented Cdc28 activity led to elevated GCR rates, whereas a reduction in Cdc28 activity resulted in suppression of GCRs. Reduced Cdc28 activity did not affect the rate of accumulation of mutations in the *CAN1*, *hom3-10*, or *lys2-Bgl* assays and did not suppress the mutator phenotype caused by an *msh2* mutation, indicating that Cdc28 specifically affects the formation of GCRs. Mutations that cause defects in mitotic checkpoint functions were previously shown to suppress the formation of GCRs ([@bib55]), indicating that mitotic checkpoint functions are required for the formation of GCRs, possibly by preventing loss of damaged chromosomes. We do not know the exact mechanism of suppression of GCR rates by the hypomorphic *cdc28-as1* and *cdc28-5M* alleles, although we can exclude a role for the Cdc28 target Sae2 because deletion of *SAE2* did not suppress the GCR rate of *mre11Δ* mutants. Although we found that Cdc28 activity by itself was not required for recovery from DNA replication arrest, it was essential when Mre11-dependent DSB repair mechanisms were defective ([Fig. 4](#fig4){ref-type="fig"}). Therefore, one explanation for the suppression of GCRs is that Cdc28 has a redundant function in the repair of damaged chromosomes and cooperates with different DNA repair pathways to promote cell viability by repairing DSBs or by healing broken chromosomes in a GCR-prone manner. For instance, Cdc28 has been found to be required for HR ([@bib29]), which is error free, but in the absence of HR, the cell deploys alternative chromosome healing pathways that can give rise to GCRs (for review see [@bib33]). A major pathway involved in the formation of GCRs is de novo telomere addition ([@bib61]). Interestingly, Cdc28 has several functions in the processing of telomeres ([@bib16]; [@bib80]; [@bib38]) and in telomeric recombination in telomerase-deficient cells ([@bib18]). Consequently, inhibiting Cdc28 activity could reduce the activity of several of the major pathways that repair and heal damaged chromosomes. The damaged chromosomes might then be lost during the next cell cycle, resulting in cell death and an apparent suppression of GCR rates. A similar model has been proposed previously to explain suppression of GCRs by mutations in mitotic checkpoint genes ([@bib55]). Suppression of GCR rates through loss of damaged chromosomes resulting in cell death is supported by several of our other findings, including (a) hypomorphic *cdc28* alleles show strong growth defects when combined with mutations like *mre11Δ* and *rad27Δ*, which are known to cause high levels of spontaneous DSBs and increased GCR rates, (b) *cdc28-5M mre11Δ* double mutants have increased mitotic catastrophe after treatment with HU, and (c) *mre11Δ cdc28-5M* and *rad27Δ cdc28-5M* double mutants had defects in maintenance of minichromosomes (unpublished data), indicating that chromosomes might indeed be lost after being damaged in these mutants.

There may be additional explanations for suppression of GCRs by *cdc28* alleles. For example, initiation of DNA replication is controlled by Cdc28 ([@bib12]), and deletion of *CDC28* or overexpression of *CLN2-1* induces unscheduled entry into S phase, resulting in increased GCR rates ([@bib35]; [@bib76]). Introducing seven extra copies of the autonomously replicating sequence *ARSH4* between *CAN1* and *URA3* suppressed the GCR rates induced by *CLN2-1* overexpression, and, therefore, GCRs that arise by precocious S-phase entry could be a result of poor assembly of prereplicative complexes ([@bib76]). Therefore, we hypothesized that suppression of GCRs by hypomorphic *cdc28* alleles might be a result of delayed entry into S phase, allowing cells to more efficiently assemble prereplicative complexes. Interestingly, we found that the introduction of extra copies of *ARSH4* into a WT strain did not reduce GCR rates ([Table IV](#tbl4){ref-type="table"}) but, in fact, resulted in a fourfold increase in the GCR rate. Extra copies of *ARSH4* also increased the GCR rate of *mre11Δ* mutants by about fourfold ([Table IV](#tbl4){ref-type="table"}). Therefore, suppression of GCR rates by hypomorphic *cdc28* alleles does not appear to be the result of improved assembly of prereplicative complexes. An alternative explanation for suppression of GCRs in strains with hypomorphic *cdc28* alleles could be that these mutants fire their origins of replication less efficiently, resulting in a lower total number of replication forks and therefore a smaller chance of replication fork collapse and thus less damage that could lead to GCRs. However, this is not likely to be the mechanism of GCR suppression because, in that case, one would expect to see fewer Ddc2 foci during S phase in mutants with hypomorphic *cdc28* alleles, but this is not the case ([Fig. 3, A and B](#fig3){ref-type="fig"}). Furthermore, hypomorphic *cdc28* alleles did not reduce the number of Ddc2 foci in *mre11Δ* mutants during S phase, indicating that the amount of damage in these cells is not reduced, and, therefore, it is unlikely that suppression of GCR rates by *cdc28* alleles is caused by a lower amount of DNA damage.

###### 

GCR rates in mutants with seven copies of *ARSH4*

  Strain    Relevant genotype           GCR rates (×10^−10^)
  --------- --------------------------- ---------------------------------------------
  RDK3615   WT                          3.5 (1)[a](#tblfn9){ref-type="table-fn"}
  RDK6307   *sit1∷control DNA*          \<4.0 (1)[b](#tblfn10){ref-type="table-fn"}
  RDK6308   *sit1∷7xARSH4*              13.9 (4)
  RDK6311   *mre11Δ sit1∷control DNA*   2,963 (847)
  RDK6312   *mre11Δ sit1∷7xARSH4*       12,539 (3,580)

Numbers in parentheses indicate fold increase over WT. The GCR rates are shown as events per generation.

Data from [@bib9].

GCR rate could not be accurately calculated because GCRs were not detected in a large enough proportion of the cultures.

The *CDC28* genetic network
---------------------------

We identified genetic interactions between *CDC28* and genes involved in a plethora of pathways that function in DNA damage responses and in the maintenance of genome stability. These include HR, sister chromatid cohesion, the spindle checkpoint, postreplication repair, telomere maintenance, and chromatin remodeling, underscoring the importance of Cdc28 in maintenance of genome stability. Given that Cdc28 controls a wide variety of cell cycle--regulated processes, we expect that the *CDC28* genetic network is much larger than presented in this study. The finding that *CDC28* genetically interacted with factors involved in HR was unexpected because Cdc28 has previously been shown to be required for HR ([@bib2]; [@bib29]), and, therefore, one might have expected an epistatic relationship between Cdc28 and factors involved in HR. Our data indicate that although Cdc28 might have an important function in HR, it must also have additional functions in the maintenance of genome stability. Indeed, we found that Cdc28 may cooperate with Mre11 to prevent mitotic catastrophe after DNA damage during S phase, which is in line with a previous study that showed that Cdc28 prevents chromosome loss during mitosis ([@bib32]). Our finding that Cdc28 appears to be required for formation of GCRs supports the idea that it prevents loss of damaged chromosomes, although the mechanism and the relevant targets of Cdc28 in this process still need to be revealed.

Cdks and genome stability in cancer
-----------------------------------

Evasion of antigrowth signals to allow unrestricted entry into S phase is a characteristic of cancer, as is genome instability ([@bib21]), and the types of genome rearrangements that are seen in cancer parallel those of GCRs in *S. cerevisiae* ([@bib63]). Although a single Cdk (Cdc28/Cdk1) controls the cell cycle in *S. cerevisiae*, in mammalian cells, five Cdks related to Cdc28 (Cdk1, Cdk2, Cdk4, and Cdk6) have been implicated in driving the cell cycle. Recent genetic evidence identified Cdk1 as the main player, and although, under normal conditions, Cdk2, Cdk4, and Cdk6 may be more important for cycling of specialized cells, they appear to play a role in driving the cell cycle in tumor cells ([@bib44]; [@bib45], [@bib46]). Interestingly, aberrant Cdk activity induces DNA damage in mammalian cells and may contribute to genome rearrangements that are observed in cancer ([@bib5]; [@bib14]; [@bib46]). Indeed, overexpression of cyclin E leads to chromosomal instability in immortalized rat embryo fibroblasts and human breast epithelial cells ([@bib73]). Our data show that aberrant Cdk activity is not just sufficient but actually also required for formation of genome rearrangements. We also found that cells with reduced Cdk activity are greatly sensitized to DNA-damaging agents, and, furthermore, they depend heavily on pathways that are involved in DNA repair such as the Me11 DSB repair pathway and the Rad6 pathway but also on intact M-phase checkpoints. Therefore, the efficacy of current cancer treatments based on γ irradiation, DNA damage--based chemotherapy, or paclitaxel-based drugs that target microtubules might be improved by combining them with broad-range CKIs. Indeed, several ongoing clinical trials are focused on Cdks and involve combination therapies ([@bib69]; [@bib46]).

In conclusion, *CDC28* functions in a genetic network that preserves genome integrity. It cooperates with the *MRE11* pathway in recovery from DNA replication arrest by preventing mitotic catastrophe during mitosis; however, Cdc28 is also required for the formation of GCRs. Therefore, Cdc28-mediated maintenance of cell viability during DNA damage may come at a cost: genome rearrangements.

Materials and methods
=====================

Yeast strains and plasmids
--------------------------

*S. cerevisiae* strains were grown in standard YPD medium. Strains were directly derived from the S288c strain RDKY3615 using either standard gene replacement methods or intercrossing ([Table S2](http://www.jcb.org/cgi/content/full/jcb.200811083/DC1)). To construct the *cdc28-as1* strain, the coding region of *cdc28-as1* was amplified from pRS306--*cdc28-as1* (gift from K. Shokat, University of California, San Francisco, San Francisco, CA) and subcloned into pRS303 and pRS304. Subsequently, a PCR product spanning the coding sequences of *cdc28-as1* and either *HIS3* or *TRP1* was used to transform RDK3615. Positive clones were identified by sensitivity to 1-NM-PP1. Sequencing revealed that two sites differed from the published sequence: A24C and T874C (resulting in Thr8Pro and Ile291Thr). These mutations did not affect sensitivity to 1-NM-PP1 ([Fig. 1](#fig1){ref-type="fig"} and not depicted). To construct the *cdc28-5M* strain, a region spanning the coding sequences of *cdc28-5M* and *TRP1* was PCR amplified from pRS304--*cdc28-5M* (gift from M. Cai, National University of Singapore, Singapore) and then used to transform RDK3615 to Trp^+^. Plasmids pRDK1293 and pRDK1294 were constructed by inserting a PCR product containing the nourseothricin resistance marker *NAT-NT1* into the BamHI site of yCP50-derived plasmids harboring *RAD6* and *rad6-149*, respectively, which were provided by M.A. Osley (University of New Mexico, Albuquerque, NM). To construct strains RDK6307 and RDK6308, the *SIT1* ORF was replaced with a PCR product spanning either part of plasmid YIplac204, including the *TRP1* marker or part of plasmid YIplac204--*7xARSH4* linked to *TRP1*, respectively. Both plasmids were provided by J.D. Diffley (Cancer Research UK London Research Institute, Hertfordshire, England, UK).

Sensitivity to chronic exposure to DNA-damaging agents and genetic interaction screen
-------------------------------------------------------------------------------------

10-fold dilutions of log-phase cell cultures were spotted on YPD supplemented with drugs, as indicated in the figures and figure legends, and incubated at 30°C, and pictures were taken when colonies were visible. UV irradiation was performed using a UV cross-linker (model 2400; Stratalinker). Genetic interactions with *cdc28-as1* were determined by spotting mutants on YPD or on YPD containing the indicated concentrations of 1-NM-PP1.

Cell survival after short treatments with drugs
-----------------------------------------------

Cells from log-phase cultures were arrested in 10 µg/ml α factor for 3 h and released into YPD for 30 min to allow cells to pass Start and enter S phase, which is a Cdc28-dependent event. As indicated, 10 µM 1-NM-PP1 (experiments involving *cdc28-as1* mutants) was added for 5 min before cells were treated with 200 mM HU, 0.05% MMS, or 0.1, 0.3, or 1 µg/ml phleomycin for 2 h, as indicated; alternatively, in experiments involving *cdc28-5M*, cells were incubated in a 42°C water bath for 5 min to rapidly inactivate Cdc28-5M before incubating at 37°C in the presence of drugs. Cells were then washed, plated on YPD plates, and incubated at 30°C until colonies appeared. Colonies were counted, and cell survival was calculated as the percentage of the colony-forming units of untreated WT cells. To determine cell survival of 1-NM-PP1--mediated cell cycle arrest, log-phase cell cultures were arrested with 10 µM 1-NM-PP1 for 3 or 8 h before being washed and plated on YPD. Cell survival was then calculated as described above.

Determination of Ddc2 foci
--------------------------

Log-phase cells were arrested in 10 µg/ml α factor for 3 h and released into YPD supplemented with 15 µg/ml nocodazole (to prevent untreated cells from entering the next cell cycle) for 30 min to allow cells to enter S phase. 10 µM 1-NM-PP1 was then added for 5 min, and cells were either left untreated or treated with 1 µg/ml phleomycin for 2 h. Cells were transferred to ice until imaged. Ddc2-GFP foci in living cells were visualized in YPD at RT with an inverted microscope (Eclipse TE300; Nikon) equipped with a 100× NA 1.40 Plan-Apochromat objective lens (Nikon), using a charge-coupled device camera (Orca-ER; Hamamatsu Photonics) and MetaMorph software (MDS Analytical Technologies). Images were processed using Photoshop (Adobe) and Illustrator (Adobe). At least 100 cells were counted, and the number of cells with at least one Ddc2-GFP focus was calculated as the percentage of the total cell population of that specific sample.

GCR assays and fluctuation assays
---------------------------------

GCR rates and fluctuation rates using the *CAN1*, *lys2-Bgl*, and the *hom3-10* assays were determined as described previously ([@bib47]; [@bib20]; [@bib77]; [@bib78]; [@bib79]; [@bib9]).

Bioinformatics
--------------

Identification of components of the *CDC28* genetic network involved in the preservation of genome stability was performed as described previously ([@bib25]), with some modifications. In brief, a *Saccharomyces* Genome Database search was conducted with a query set of genes that showed the strongest genetic interactions with *CDC28* (*RAD53*, *MRE11*, *RAD50*, *RAD52*, *BUB2*, *BUB3*, *MAD2*, *CTF4*, *CTF18*, *CSM3*, *RAD6*, *RAD18*, *RAD5*, *ASF1*, *POL32*, *RAD27*, and *TLC1*) followed by data sorting with Excel (Microsoft). This dataset was then filtered by discarding all genes having less than five genetic interactions in common with the set of query genes to remove false interactions. Predictions of genetic interactions that we already tested in our initial screen were discarded. Finally, the remaining genes were grouped according to gene ontology annotations, and those gene ontology groups that contained genes that tested negative in our initial screen for genetic interaction with *CDC28* were discarded.

Western blotting
----------------

Cell pellets were resuspended in 20% TCA and disrupted by vortexing at 4°C for 15 min in the presence of glass beads. Lysates were centrifuged, pellets were washed with 70% ethanol and resuspended in Laemmli sample buffer, and the pH was neutralized using Tris base. Lysates were boiled, centrifuged, and resolved on SDS-PAGE followed by Western blotting using HRP-coupled Flag antibodies (Sigma-Aldrich).

FACS analysis
-------------

Cells were fixed in 70% ethanol for 1 h at RT, harvested by centrifugation, and resuspended in 50 mM sodium citrate buffer, pH 7.0. Cells were sonicated (three pulses of 1 s each), centrifuged, resuspended in sodium citrate buffer containing 250 µg/ml RNase A and 1 mg/ml proteinase K, and incubated overnight at 37°C. The cells were then harvested by centrifugation, resuspended in 1 ml of sodium citrate buffer containing 1 µM Sytox green (Invitrogen), and incubated at RT for at least 1 h before being analyzed by FACS.

PFGE
----

Overnight cultures of the indicated strains were diluted in fresh YPD and allowed to resume growth at 30°C to reach ∼10^7^ cells/ml (hemocytometer readings). 10 ml from each culture was centrifuged, and cells were fixed with 70% ethanol for at least 1 h at RT. The remaining culture of each strain was synchronized by the addition of HU (Sigma-Aldrich) to a final concentration of 0.2 M. After incubation at 30°C for 2 h, the majority of the cells (\>90%) was arrested in S phase with large buds. Aliquots were taken and fixed in 70% ethanol. The remaining culture was washed to remove HU and resuspended in fresh YPD containing 10 µg/ml α factor (Sigma-Aldrich). After incubation at 30°C (or 37°C as indicated) for 3 h, samples were collected, and cells were fixed in 70% ethanol as above. Preparation of agarose-embedded yeast DNA was performed with contour-clamped homogeneous electric field (CHEF) genomic DNA plug kit (Bio-Rad Laboratories) according to the manufacturer\'s instructions. 6 × 10^7^ fixed cells were washed and set into each agarose plug. All plugs were subsequently treated with lyticase and proteinase K before loading onto an agarose separation gel (1% Megabase agarose; Bio-Rad Laboratories). PFGE was run in CHEF Mapper equipment (Bio-Rad Laboratories) in 0.5× Tris-borate-EDTA buffer at 14°C with an angle of 120°, a voltage gradient of 6 V/cm, and switch times of 60 s for 15 h and 90 s for 7 h. The gel was stained with ethidium bromide before being photographed. The relative amount of DNA fragmentation was determined as follows. Part of the fragmented DNA of subchromosomal size (Fig. S2) was quantified using the histogram tool of Photoshop and corrected for background noise. This was then normalized against the amount of DNA of chromosome XI (quantified and corrected in the same way). The mean and standard error of the mean were then calculated using data from three independent experiments. Only treatments at 30°C were analyzed because incubation at 37°C did not further increase chromosome fragmentation.

Online supplemental material
----------------------------

Fig. S1 shows that Cdc28 functions in the DNA damage response but is not important for survival of acute DNA damage. Fig. S2 shows an example of a PFGE gel. Fig. S3 quantifies the genetic interactions of several genes with *CDC28*. Table S1 displays the predicted as well as confirmed genetic interactions with *CDC28* using a bioinformatics approach. Table S2 shows the yeast strains used in this study. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.200811083/DC1>.
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